Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Applied BioCodeTPE:6598 -3.63%75 PB Ratio is 4.03 as of Jul. 16, 2026, which is 22% above its 10-year median of 3.31. GuruFocus rates TPE:6598 with a GF Score™ of 75/100 and a GF Value™ of NT$23.34 (Fairly Valued). The stock has 6 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Applied BioCode ranks worse than 75.35% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), Applied BioCode's share price is NT$25.20. Applied BioCode's Book Value per Share for the quarter that ended in Dec. 2025 was NT$6.26. Hence, Applied BioCode's PB Ratio of today is 4.03.
Warning Sign:
Applied BioCode Corp stock PB Ratio (=3.65) is close to 1-year high of 4.04.
The historical rank and industry rank for Applied BioCode's PB Ratio or its related term are showing as below:
TPE:6598'
s PB Ratio Range Over the Past 10 Years
Min: 2.22 Med: 3.31 Max: 24.71
Current: 4.03
During the past 13 years, Applied BioCode's highest PB Ratio was 24.71. The lowest was 2.22. And the median was 3.31.
TPE:6598's PB Ratio is ranked worse than 75.35% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs TPE:6598: 4.03
During the past 12 months, Applied BioCode's average Book Value Per Share Growth Rate was -26.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -12.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -11.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Applied BioCode was 35.10% per year. The lowest was -23.10% per year. And the median was -6.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Applied BioCode PB Ratio Related Terms
Applied BioCode PB Ratio Historical Data
* Premium members only.
The historical data trend for Applied BioCode's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Applied BioCode's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's PB Ratio distribution charts can be found below:
* The bar in red indicates where Applied BioCode's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Applied BioCode's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Applied BioCode (TPE:6598) has a PB Ratio of 4.03 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Applied BioCode and its competitors. This is 22% above median its historical median of 3.31. Over the past decade, Applied BioCode's PB Ratio has ranged from 2.22 to 24.71. According to the industry distribution chart, Applied BioCode ranks #593 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 75.3%.
Is Applied BioCode's PB Ratio too high?
Applied BioCode's current PB Ratio of 4.03 is 22% above median its 10-year median of 3.31. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 24.71. The Medical Devices & Instruments industry median PB Ratio is 2.05. Applied BioCode's value of 4.03 is 96.6% above this industry median. Based on the distribution chart, Applied BioCode ranks #593 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Applied BioCode has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #593 out of 787 companies for PB Ratio. This places Applied BioCode in the lower half of its industry. The industry median PB Ratio is 2.05. Applied BioCode's value of 4.03 is 96.6% above this benchmark. Historically, Applied BioCode's own PB Ratio has ranged from 2.22 to 24.71 over the past decade. While the company's 10-year median is 3.31 vs. the industry median of 2.05, Applied BioCode has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Applied BioCode's current PB Ratio of 4.03 is 96.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Applied BioCode and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current PB Ratio is 4.03, which is 22% above median its own 10-year median of 3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$23.34, compared to a current price of NT$25.20 — trading 8% above its estimated fair value. The current PB Ratio is 4.03, which is 22% above median its 10-year median of 3.31 and 96.6% above the Medical Devices & Instruments industry median of 2.05. Applied BioCode's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current PB Ratio is 4.03 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be overvalued.
The current stock price of NT$25.20 is trading 8% above its estimated GF Value™ of NT$23.34.
GuruFocus considers Applied BioCode to be Fairly Valued.
Key valuation signals for TPE:6598:
PB Ratio: 4.03 (22% above median its 10-year median of 3.31)
GF Value™: NT$23.34 vs. price of NT$25.20 (8% above fair value)
Industry Position: 96.6% above the Medical Devices & Instruments median (#593 of 787)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
75GF Score
Get the complete analysis for TPE:6598
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
